RxDoctor Payments Data

Elizabeth Hammond, NP

Family · Lakewood, CONPI 1629580501

Payments from drug & device makers

What this record shows

23 manufacturers reported payments, led by Boston Scientific at 43.1% of the total. Reporting peaked in 2023 at $3,005 and has fallen 94.7% since, to $160 in 2025. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,090in general payments, 2019–2025

Across 212 payments — averaging $42.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Spinal Simplicity, LLC$1K
  • AbbVie$959
  • Collegium Pharmaceutical, Inc.$473
  • Pfizer$318
  • GRT US Holding, Inc.$249
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$3,82442%
  • Food & beverage$5,26658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,090 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$16,410
Medicare patients
66
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl18$12,472
Xtampza ErOxycodone Myristate16$9,237
Buprenorphine26$7,560
MovantikNaloxegol Oxalate16$6,641
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen78$3,096
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$2,676
Morphine Sulfate ErMorphine Sulfate67$1,517
Oxycodone Hcl77$1,186
Gabapentin56$750
Methocarbamol32$679
Hydromorphone Hcl36$653
Cyclobenzaprine Hcl41$638
Baclofen29$616
Tizanidine Hcl29$473
Tramadol Hcl30$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$473$21,70834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →